Browse studies

Find your next paid study

6 recruiting studies matching your filters

PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/II Platform Trial

PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed…

HER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+29 more

Estimated

~$10 – $7,500

QuantumLeap Healthcare CollaborativeNCT05868226

Phase 3

A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received…

Breast CancerLocally Advanced Breast CancerMetastatic Breast Cancer+2 more

Estimated

~$10 – $8,750

Olema Pharmaceuticals, Inc.NCT07085767

Phase 2

An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Cancers Hoosier Cancer Research Network BRE17-141

Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, …

Breast CancerHER2-positive Breast CancerER Positive Breast Cancer+1 more

Estimated

~$10 – $7,500

Ruth O'ReganNCT04886531

Observational

Supporting Health Including Endocrine Treatment for Long Duration: A Pilot Intervention

This research is being done to pilot an intervention which aims to test a new web- and mobile application ("app")-based supportive care tool (SHIELD portal) an…

Breast CancerBreast Cancer - FemaleBreast Carcinoma+2 more

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT07482384

Phase 2

DATO-BASE: A Phase 2 Trial of DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that h…

Breast CancerBreast Cancer FemaleMetastatic Triple-Negative Breast Carcinoma+4 more

Estimated

~$10 – $7,500

Nancy Lin, MDNCT06176261

Role of the Immune Environment in Response to Therapy in Breast Cancer

This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be comp…

Breast CancerER Positive Breast CancerHER2-negative Breast Cancer+1 more

Estimated

~$10 – $750

Abramson Cancer Center at Penn MedicineNCT05396612